Last update 08 May 2025
Chengdu Kanghong Biotechnologies Co., Ltd.

Chengdu Kanghong Biotechnologies Co., Ltd.

Subsidiary Company|2005|Sichuan Sheng, China

Overview

Tags

Eye Diseases
Neoplasms
Cardiovascular Diseases
Bispecific antibody
Dual payload Antibody drug conjugate (Dual payload ADC)
Antibody fusion proteins

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease2
Neoplasms2
Infectious Diseases1
Nervous System Diseases1
Top 5 Drug TypeCount
Antibody fusion proteins1
Dual payload Antibody drug conjugate (Dual payload ADC)1
Biosimilar1
Bispecific antibody1
Top 5 TargetCount
POLR2A x Top I x Trop-21
VEGF(Vascular endothelial growth factor)1
VEGF-A(Vascular endothelial growth factor A)1

Related

4
Drugs associated with Chengdu Kanghong Biotechnologies Co., Ltd.
Conbercept
Target
VEGF-A
Mechanism
VEGF-A inhibitors
Active Org.
Chengdu Kanghong Biotechnologies Co., Ltd.Chengdu Kanghong Biotechnologies Co., Ltd. [+2]
Originator Org.
Chengdu Kanghong Biotechnology Co. Ltd.
Active Indication
Retinal vein occlusion-related macular edema [+5]
Inactive Indication
Advanced Gastroesophageal Junction Adenocarcinoma [+8]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date27 Nov 2013
KH815
Target
POLR2A x Top I x Trop-2
Mechanism
POLR2A inhibitors [+2]
Active Org.
Kanghong Biotechnology Group Co., Ltd. [+2]
Originator Org.
Chengdu Kanghong Biotechnologies Co., Ltd.Chengdu Kanghong Biotechnologies Co., Ltd.
Active Indication
Advanced Malignant Solid Neoplasm [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
CN115703838
Patent Mining
Target
VEGF
Mechanism-
Active Org.
Chengdu Kanghong Biotechnologies Co., Ltd.Chengdu Kanghong Biotechnologies Co., Ltd.
Originator Org.
Chengdu Kanghong Biotechnologies Co., Ltd.Chengdu Kanghong Biotechnologies Co., Ltd.
Active Indication
Cardiovascular Diseases [+7]
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
20
Clinical Trials associated with Chengdu Kanghong Biotechnologies Co., Ltd.
NCT06885645
/ Not yet recruitingPhase 1
A Phase 1 Study of KH815 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients With Advanced Solid Tumors
NCT04985448
/ Unknown statusNot Applicable
Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data
NCT04990271
/ Unknown statusPhase 2
A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma
100 Clinical Results associated with Chengdu Kanghong Biotechnologies Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Chengdu Kanghong Biotechnologies Co., Ltd.
Login to view more data
100 Deals associated with Chengdu Kanghong Biotechnologies Co., Ltd.
Login to view more data
100 Translational Medicine associated with Chengdu Kanghong Biotechnologies Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
1
IND Application
Phase 1 Clinical
1
1
Approved
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Conbercept
 ( VEGF-A )		Choroidal Neovascularization
More
Approved
KH815
 ( POLR2A x Top I x Trop-2 )		Advanced Malignant Solid Neoplasm
More
Phase 1
KH813
-
IND Application
CN115703838
 ( VEGF )		Nervous System Diseases
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free